EUVIMEDEUVIMED entdecken
Open Access

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Simone Lubrano, Rodolfo Daniel Cervantes-Villagrana, Farhoud Faraji, Sydney Ramirez, Kuniaki Sato, Sendi R Adame-Garcia, Adam Officer, Nadia Arang, Damiano C Rigiracciolo, Paola Y Anguiano Quiroz, Claudia Martini, YiYu Wang und 8 weitere

Cancer Cell · 2025-03 · 43 (3) · 428-445.e6

DOI: 10.1016/j.ccell.2025.02.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-03. Verfasst von Simone Lubrano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; De…. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Widespread BRAF mutations result in persistent RAS-RAF-MEK-ERK (MAPK) signaling in melanoma. BRAF (BRAFi) and MEK (MEKi) inhibitors are approved for BRAF V600E melanomas, including those progressing on immunotherapy; however, rapid resistance to these agents highlights the need for novel strategies. Here, transcriptome analysis of BRAF V600E melanomas from patients resistant to BRAFi and MEKi shows activation of focal adhesion signaling. Consistently, BRAFi, MEKi, and the RAF-MEK clamp avutometinib activate focal adhesion kinase (FAK) in melanoma cells. Mechanistically, inhibition of an MAPK-RhoE (RND3) feedback loop results in the adaptive activation of RhoA-FAK-AKT. In turn, FAK inhibitors (FAKi) exert potent pro-apoptotic activity when combined with MAPK pathway inhibition. FAKi plus avutometinib overcomes resistance in multiple models derived from BRAFi plus MEKi-resistant melanoma patients and immunotherapy-resistant syngeneic mouse models. These findings provide a rationale for the development of avutometinib in combination with FAKi for patients with BRAF V600E melanoma progressing on BRAFi plus MEKi or immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafDrug Resistance, NeoplasmProtein Kinase InhibitorsFocal Adhesion Kinase 1Antineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceCell Line, TumorImmunotherapyMutationApoptosisMAP Kinase Signaling SystemXenograft Model Antitumor Assays

Stichwörter der Autor:innen

BRAFFAKMAPK signalingMEKavutometinibimmunotherapymelanomaresistancesignal transductiontargeted therapies

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanProtein Kinase InhibitorsFocal Adhesion Kinase 1PTK2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Department of Pharmacology, School of Medicine, University of California…
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Department of Otolaryngology - Head and Neck Surgery, UC San Diego Health, La Jolla, CA 92037, USA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; John Muir College, University of California, San Diego, La Jolla, CA 92093, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NLM NIH HHS
  • NIDCD NIH HHS
  • European Commission Marie Sklodowska-Curie Actions
  • NIH National Institute of General Medical Sciences
  • National Institutes of Health National Cancer Institute
  • Horizon 2020 Framework Programme

Zitieren

APA

Lubrano, S., Cervantes-Villagrana, R. D., Faraji, F., Ramirez, S., Sato, K., Adame-Garcia, S. R., Officer, A., Arang, N., Rigiracciolo, D. C., Anguiano Quiroz, P. Y., Martini, C., Wang, Y., Ferguson, F. M., Bacchiocchi, A., Halaban, R., Coma, S., Holmen, S. L., Pachter, J. A., Aplin, A. E., & Gutkind, J. S. (2025). FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell, 43(3), 428-445.e6. https://doi.org/10.1016/j.ccell.2025.02.001

Vancouver

Lubrano S, Cervantes-Villagrana RD, Faraji F, Ramirez S, Sato K, Adame-Garcia SR, et al. FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell. 2025;43(3):428-445.e6. doi:10.1016/j.ccell.2025.02.001

BibTeX
@article{Lubrano2025,
  author = {Lubrano, Simone and Cervantes-Villagrana, Rodolfo Daniel and Faraji, Farhoud and Ramirez, Sydney and Sato, Kuniaki and Adame-Garcia, Sendi R and Officer, Adam and Arang, Nadia and Rigiracciolo, Damiano C and Anguiano Quiroz, Paola Y and Martini, Claudia and Wang, YiYu and Ferguson, Fleur M and Bacchiocchi, Antonietta and Halaban, Ruth and Coma, Silvia and Holmen, Sheri L and Pachter, Jonathan A and Aplin, Andrew E and Gutkind, J Silvio},
  title = {FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {428--445.e6},
  doi = {10.1016/j.ccell.2025.02.001}
}
Kostenlos starten →